The combination of PD-L1 blocker and gemcitabine has been proved to have antitumor effect in the treatment of pancreatic cancer, while the clinical response rate of the combination of pembrolizumab/gemcitabine + albumin-bound paclitaxel in the treatment of pancreatic cancer is up to 92% [29]. This evidence concerns the gene ALB and familial pancreatic carcinoma.